A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life

Enfuvirtide (T20) is the first U.S. FDA-approved HIV fusion inhibitor-based anti-HIV drug. Its clinical application is limited because of its low potency and short half-life. We previously reported that peptide HP23-E6-IDL, containing both N- and C-terminal anchor-tails, exhibited stronger potency a...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shan, Rasquinha, Giselle, Du, Lanying, Wang, Qian, Xu, Wei, Li, Weihua, Lu, Lu, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470885/
https://www.ncbi.nlm.nih.gov/pubmed/30901967
http://dx.doi.org/10.3390/molecules24061134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470885/
https://www.ncbi.nlm.nih.gov/pubmed/30901967
http://dx.doi.org/10.3390/molecules24061134

Ejemplares similares